Eikon Therapeutics, Inc. (EIKN)

NASDAQ: EIKN · USD

$5.53

-0.02 (-0.4%)· Recorded snapshot

Market cap	299.3M
Net income (ttm)	-322.2M
EPS (ttm)	-$13.7
Shares out	54.2M
Volume	616,445

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -322.2M
EPS (ttm): -$13.7
Market cap: 299.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All EIKN indicators

Market & fundamental data

Available fields

155

Groups with data

Currency

USD

Showing 155 of 155 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001861123
Company name	Eikon Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	282564103
Earnings date	2026-11-10
Earnings time	amc
Employees	384
Enterprise value	$20.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2019
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2026-02-05
Is primary listing	Yes
Is SPAC	No
ISIN number	US2825641036
Last 10-K release date	2026-03-30
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$299.3M
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	No
Price	$5.53
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	EIKN
Tags	pharmaceuticals
U.S. state	California
Website	https://eikontx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-248.36%
FCF / EV yield	-957.39%
FCF yield	-84.7%
P/B ratio	0.64x
Price / tangible book value	0.66x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-838,961
ROCE	-46.73%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	0
Net income growth quarters	1
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-3.2M
Depreciation and amortization	$21.2M
EBIT	$-338.4M
EBITDA	$-317.2M
EPS	$-13.72
FCF per share	$-4.79
Financing cash flow	$350.6M
Free cash flow	$-259.2M
Free cash flow minus SBC	$-274M
Investing cash flow	$-88.4M
Net cash flow	$6.2M
Net income	$-322.2M
Operating cash flow minus SBC	$-270.9M
Operating income	$-338.4M
Stock-based compensation	$14.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$8.62
Debt / equity	0.54
Interest coverage	-404.36
Long-term assets	$232.6M
Long-term liabilities	$257.8M
Net cash (debt)	$279M
Net cash / market cap	91.15%
Net cash growth	1,480.33%
Net debt / equity	-0.6
Piotroski F-Score	2
Property, plant and equipment	$224.2M
Shareholders' equity	$466.5M
Tangible book value	$466.5M
Tangible book value per share	$8.62
Total assets	$779.6M
Total cash	$531.2M
Total debt	$252.2M
Total liabilities	$313.1M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$547M
Current liabilities	$55.3M
Current ratio	9.89
Net working capital	$-30.1M
Quick ratio	9.61
Working capital	$491.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-831.8%
Dividend yield	0%
Shareholder yield	-831.8%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$9.75
1D price change	-0.36%
1M price change	-30.05%
1M total return	-30.05%
1W price change	-32.27%
1W total return	-32.27%
20-day SMA	$7.21
3M price change	-43.93%
3M total return	-43.93%
50-day SMA	$8.83
52-week high	$17.40
52-week high date	2026-02-05
52-week low	$5.32
52-week low date	2026-10-28
6M price change	-36.61%
6M total return	-36.61%
All-time high	$17.40
All-time high date	2026-02-05
All-time low	$5.32
All-time low date	2026-10-28
Average true range (ATR)	$0.72
Average volume	532.5K
Beta (1Y)	1.84
Change from 52-week high	-68.25%
Change from 52-week low	3.85%
Change from all-time high	-68.16%
Change from all-time low	4.14%
Change from open	0.09%
Day's gap	-0.54%
Dollar volume	$3.4M
High price	$5.70
Low price	$5.35
Monthly RSI	0
Open price	$5.52
Position in 52-week range	50%
Premarket change	0.99%
Premarket close	$5.55
Premarket price	$5.60
Previous close	$5.55
Price vs 150-day SMA	-43.16%
Price vs 20-day SMA	-23.19%
Price vs 50-day SMA	-37.28%
Relative volume	1.16
Return from IPO open	-66.86%
Return from IPO price	-68.61%
RSI	29.5
Sharpe ratio	-1.05
Sortino ratio	-1.35
Volume	616.4K
Weekly RSI	29.14

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	34.8M
Float percentage	64.21%
Shares change (QoQ)	60.66%
Shares change (YoY)	831.8%
Shares held by insiders	6.26%
Shares held by institutions	51.75%
Shares outstanding	54.2M
Short % of float	18.32%
Short % of shares	11.76%
Short ratio	9.8 days

Deeper analysis on EIKN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this EIKN report

Is a complete EIKN research report available?

No complete published report is available for Eikon Therapeutics, Inc. (EIKN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Eikon Therapeutics, Inc. (EIKN)

Price

Financial snapshot

Fair-value bridge

Latest news · EIKN

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All EIKN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on EIKN

Frequently asked questions